60 Degrees Pharmaceuticals, Inc. (SXTP) Price & Analysis

Compare

182 Followers

SXTP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.26 - $12.71

Previous CloseN/A

Volume13.44M

Average Volume (3M)1.07M

Market Cap

$4.36M

Enterprise Value$8.55M

Total Cash (Recent Filing)$3.45M

Total Debt (Recent Filing)$155.27K

Price to Earnings (P/E)―

Beta2.33

Next Earnings

Nov 13, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.25

Shares Outstanding3,226,205

10 Day Avg. Volume153,678

30 Day Avg. Volume1,074,629

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.96

Enterprise Value/Revenue13.05

Enterprise Value/Gross Profit32.54

Enterprise Value/Ebitda-0.83

Forecast

1Y Price Target

$4.00

Price Target Upside196.30% Upside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Market OpportunityThe company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.

Product RevenueProduct revenues showed a significant year-over-year increase, despite being supply-constrained.

Sales GrowthArakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.

Bears Say

Clinical TrialsPatients are currently enrolling in an ongoing company-sponsored randomized, double-blind, multisite, placebo-controlled Phase 2/3 trial evaluating the efficacy and safety of the Arakoda regimen of tafenoquine at 800mg in combination with standard of care medications.

EarningsQ1 earnings per share were below estimates due to higher than forecast SG&A expenses.

60 Degrees Pharmaceuticals, Inc. News

60 Degrees Pharmaceuticals, Tulane University sign research agreement

60 Degrees Pharmaceuticals (SXTP) announced its entry into a sponsored research agreement with Tulane University to evaluate activity...

28d ago

SXTP

60 Degrees Pharmaceuticals prices 2.6M shares at $1.90 in public offering

60 Degrees Pharmaceuticals (SXTP) announced the pricing of a public offering of 2,631,578 shares of the Company’s common...

30d ago

SXTP

60 Degrees determines max commercial market size for ARAKODA at $245M annually

60 Degrees Pharmaceuticals (SXTP) announced it has determined the maximum size of the commercial market for ARAKODA for...

30d ago

SXTP

60 Degrees Pharmaceuticals Reports Q2 2025 Earnings

60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has released its Q2 earnings. Here is a breakdown of the...

2h ago

SXTP

SXTP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

60 Degrees Pharmaceuticals, Inc. (SXTP) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall...

3d ago

SXTP

60 Degrees Pharmaceuticals Secures $5M in Recent Offering

60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has provided an announcement. On July 15, 2025, 60 Degrees Pharmaceuticals,...

26d ago

SXTP

60 Degrees Pharmaceuticals to submit tafenoquine MUMS designation request to FDA

60 Degrees Pharmaceuticals (SXTP) announced that the company will conduct a gap analysis of its existing data prior...

1M ago

SXTP

Closing Bell Movers: Merit Medical Systems gains after Q2 outlook

In the opening hour of the evening session, U.S. equity futures are down again following a post-holiday session...

1M ago

BIIB

MMSI

60 Degrees Pharmaceuticals to sell 2.04M shares of common stock for holders

17:52 EDT 60 Degrees Pharmaceuticals (SXTP) to sell 2.04M shares of common stock for holders Published first on...

1M ago

SXTP

60 Degrees introduces eight-count bottle format for ARAKODA

60 Degrees Pharmaceuticals (SXTP) announced the introduction of a new 8-count bottle format for ARAKODA. The 8-count bottle...

2M ago

SXTP

60 Degrees announces results from an insurance claims analysis on babesiosis

60 Degrees Pharmaceuticals (SXTP) announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as...

2M ago

SXTP

60 Degrees announces findings from online survey about babesiosis disease

60 Degrees Pharmaceuticals (SXTP)announced findings that the actual burden of babesiosis in the United States may be significantly...

4M ago

SXTP

60 Degrees Pharmaceuticals signs Patient License Agreement with Yale

60 Degrees Pharmaceuticals (SXTP) announced the signing of a Patent License Agreement with Yale School of Medicine and...

4M ago

SXTP

Upcoming Stock Splits This Week (February 24 to February 28) – Stay Invested

These are the upcoming stock splits for the week of February 24 to February 28, based on TipRanks’ Stock...

6M ago

GRI

APTO

SXTP FAQ

What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?

60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.26 and its highest was $12.71 in the past 12 months.

What is 60 Degrees Pharmaceuticals, Inc.’s market cap?

60 Degrees Pharmaceuticals, Inc.’s market cap is $4.36M.

When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?

60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 13, 2025 which is in 91 days.

How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?

60 Degrees Pharmaceuticals, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$1.24 by -$0.01.

Is 60 Degrees Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does 60 Degrees Pharmaceuticals, Inc. pay dividends?

60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.

What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?

60 Degrees Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?

60 Degrees Pharmaceuticals, Inc. has 3,226,205 shares outstanding.

What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?

60 Degrees Pharmaceuticals, Inc. reported an EPS of -$1.25 in its last earnings report, missing expectations of -$1.24. Following the earnings report the stock price went up 14.884%.

Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in SXTP

Company Description

60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

60 Degrees Pharmaceuticals, Inc. (SXTP) Earnings & Revenues

Historic Earnings Reports

SXTP Stock 12 Month Forecast

Average Price Target

$4.00

▲(196.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","4.5":"$4.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.37,2.726153846153846,3.082307692307692,3.4384615384615387,3.7946153846153847,4.150769230769231,4.506923076923077,4.863076923076923,5.219230769230769,5.575384615384616,5.931538461538461,6.287692307692308,6.643846153846154,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.37,2.4953846153846153,2.620769230769231,2.746153846153846,2.871538461538462,2.996923076923077,3.1223076923076922,3.247692307692308,3.373076923076923,3.4984615384615383,3.623846153846154,3.749230769230769,3.8746153846153844,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.37,2.264615384615385,2.1592307692307693,2.053846153846154,1.9484615384615385,1.8430769230769233,1.7376923076923076,1.6323076923076925,1.5269230769230768,1.4215384615384616,1.3161538461538462,1.2107692307692308,1.1053846153846154,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.46,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.63,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >